Pregabalin

Formulation

The table below describes the formulation of pregabalin and the controls morphine sulfate and gabapentin for the experiments shown on this page.

Experiment(s) Compound Dose(s) mg/kg Correction factor Dose volume mL/kg Route Vehicle Suspension / Solution
Pharmacokinetics Pregabalin 30 1.00 1 PO Saline Solution
Irwin, Rotarod Pregabalin 10, 30, 60, 100 1.00 5 PO Saline Solution
Plantar incision, MIA Pregabalin 10, 30, 60 1.00 5 PO Saline Solution
L5/L6 SNL Pregabalin 10, 30, 60 1.00 1 PO Saline Solution
Plantar incision, Morphine 6 1.33 1 SC Saline Solution
L5/L6 SNL (Acetone), MIA
L5/L6 SNL (von Frey) Gabapentin 60 1.00 1 PO Saline Solution

L5/L6 SNL = L5/L6 spinal nerve ligation; MIA = monosodium iodoacetate; PO = per os; SC = subcutaneous


Results

Expand and Collapse accordion content

Method: Rat Rotarod
Two graphs show the latency for male or female rats to fall off a rotarod apparatus. Responses are shown at the following time points: baseline (before treatment) and at 1, 2, 4, and 6 hours after treatment with vehicle (saline, delivered PO) or pregabalin (10, 30, 60, or 100 mg/kg, delivered PO). There were 10 rats per group. Neither males nor females had a significant interaction of time x treatment in a two-way repeated measures ANOVA, but a significant effect of treatment was found for each sex. Bonferroni’s tests found a significant decrease in the latency to fall relative to vehicle in males after treatment with 60 mg/kg pregabalin (p<0.01) and 100 mg/kg pregabalin (p<0.0001). Bonferroni’s tests found a significant decrease in the latency to fall relative to vehicle in females after treatment with 30 mg/kg pregabalin (p<0.01), 60 mg/kg pregabalin (p<0.05), and 100 mg/kg pregabalin (p<0.0001).


This work was conducted by PsychoGenics Inc. (Paramus, NJ) in collaboration with PSPP, NINDS, NIH under contract # 75N95019D00026. Prescribing information for clinically used controls can be found at labels.fda.gov.